HAE
$87.61
Haemonetics
($.14)
(.16%)
HAE
Earnings Whisper ®
N/A
1st Quarter June 2023
Consensus:  $0.76
Revenue:  $289.55 Mil
Thursday
Aug 10
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when HAE reports earnings?
Beat
Meet
Miss

Where is HAE's stock price going from here?
Up
Flat
Down
Stock chart of HAE
Analysts
Summary of analysts' recommendations for HAE
Score
Grade
Pivots
Resistance
$90.53
$89.63
$88.69

$87.79

Support
$86.85
$85.95
$85.01
Tweet
Growth
Description
Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.
Peers
StrykerAbbottBoston ScientificBaxter InternationalTeleflexBecton, Dickinson3MWatersResMedIntegra LifeSciences Holdings